FDA Approves HETLIOZ — Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc.'s oral drug TASIMELTEON has received FDA approval, representing a potential therapeutic option for a previously underserved patient population. The company's execution in this niche market is likely to drive growth and strengthen its revenue streams following regulatory validation.